Leukemia Research
Volume 27, Issue 1 , Pages 1-3 , January 2003

Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?

References 

  1. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Ann. Rev. Biochem. 2001;70:369–413
  2. Li T-K, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Ann. Rev. Pharmacol. Toxicol. 2001;41:53–77
  3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000;343:905–914
  4. Kantarjian HM, Beran M, Ellis A, Zwelling L, O’Brien S, Cazenave L, et al.  Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993;81:1146–1151
  5. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, et al.  Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol. 1994;12:2193–2203
  6. Rowinsky EK, Kaufmann SH, Baker S, Miller C, Sartorius SE, Bowling K, et al.  A phase I and pharmacologic study of topotecan on a 30 minute infusion daily for five day schedule in patients with refractory acute leukemia. Clin. Cancer Res. 1996;2:1921–1930
  7. Beran M, Kantarjian H, O’Brien S, Koller C, Al-Bitar M, Arbuck S, et al.  Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996;88:2473–2479
  8. Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, et al.  A phase II window study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin. Cancer Res. 1998;4:2677–2689
  9. Beran M, Estey E, O’Brien S, Cortes J, Koller CA, Giles FJ, et al.  Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin. Oncol. 1999;17:2819–2830
  10. Seiter K, Feldman EJ, Halicka HD, Traganos F, Darzynkiewicz Z, Lake D, et al.  Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J. Clin. Oncol. 1997;15:44–51
  11. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom DX, et al.  Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. 1996;14:3074–3084
  12. Cortes J, Estey E, Beran M, O’Brien S, Giles F, Koller C, et al.  Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk. Lymphoma. 2000;36:479–484
  13. Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991;51:1129–1136
  14. Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother. Pharmacol. 1996;39:109–112
  15. Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, et al.  Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 1999;13:343–347
  16. Dowlati A, Levitan N, Gordon NH, Hoppel CL, Gosky DM, Remick SC, et al.  Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2001;47:141–148
  17. Huisman C, Postmus PE, Giaccone G, Smit EF. A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. Ann. Oncol. 2001;12:1567–1573
  18. Herben VM, Bokkel Huinink WW, Dubbelman AC, Mandjes IA, Groot Y, van Gortel-van Zomeren DM, et al.  Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br. J. Cancer. 1997;76:1500–1508
  19. Hammond LA, Eckardt JR, Ganapathi R, Burris HA, Rodriguez GA, Eckhardt SG, et al.  A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin. Cancer Res. 1998;4:1459–1467
  20. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, et al.  Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood. 1994;83:517–530
  21. Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, et al.  Factors affecting topotecan sensitivity in human leukemia samples. Ann. New York Acad. Sci. 1997;803:128–142
  22. Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke TX, Buckwalter CA, et al.  Factors affecting topotecan sensitivity in human leukemia samples. Ann. New York Acad. Sci. 1996;803:128–142
  23. Saleem A, Edwards TK, Rasheed Z, Rubin EH. Mechanisms of resistance to camptothecins. Ann. N.Y. Acad. Sci. 2000;922:46–55
  24. Fiorani P, Bjornsti MA. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann. N.Y. Acad. Sci. 2000;922:65–75
  25. Champoux JJ. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann. N.Y. Acad. Sci. 2000;922:56–64
  26. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood. 1997;89:2098–2104
  27. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol. Res. 1993;5:467–474
  28. Hoki Y, Fujimori A, Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. 1997;40:433–438
  29. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992;52:2268–2278
  30. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr. Opin. Oncol. 2001;13:453–462
  31. Smith BD, Bambach BJ, Vala MS, Barber JP, Enger C, Brodsky RA, et al.  Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br. J. Haematol. 1998;102:1042–1049

PII: S0145-2126(02)00219-9

Leukemia Research
Volume 27, Issue 1 , Pages 1-3 , January 2003

Article Tools